HLB Pep Gains TFDA Approval for Desmopressin API

HLB Pep logo

 

HLB Pep, a South Korean peptide biomaterials company formerly known as ANYGEN, announced that its desmopressin API has been approved by Taiwan's TFDA—a key step in its global expansion strategy. Desmopressin treats conditions like bedwetting and diabetes insipidus, in a global market worth $1.4 billion. 

As Korea's only GMP-certified peptide producer, HLB Pep aims to shift from domestic sales to international markets, leveraging its integration with HLB Group to boost liquidity and global reach. The company is also pursuing U.S. FDA certification and expanding CDMO operations in Japan while developing new therapies for obesity, diabetes, and ulcerative colitis.

Read more: https://www.ittimes.com/news/articleView.html?idxno=75863

HLB Pep Secures Taiwan Drug Approval for Desmopressin API - IT타임스